Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terephthalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295509 | 0.82 | KMT2A (0.41) | TDP1SMN1; SMN2 | |
| SCHEMBL5528 | 0.82 | — | — | |
| Charcoal, Activated SCHEMBL8216968 | 0.80 | — | — | |
| Water SCHEMBL9815377 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL10608471 | 0.80 | — | — | |
| Formaldehyde SCHEMBL9633220 | 0.80 | KMT2A (0.40) | TDP1SMN1; SMN2 | |
| Styrene SCHEMBL990787 | 0.79 | ALDH1A1 (0.47) | TSHRELANEALDH1A1L3MBTL1LMNA | |
| Acrylic Acid SCHEMBL20490 | 0.79 | LMNA (0.43) | ELANELMNAALOX15 | |
| SCHEMBL16176164 | 0.79 | PLG (0.39) | TSHRELANELMNA | |
| Acetic Acid SCHEMBL585034 | 0.79 | KMT2A (0.36) | TSHRELANEALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4362921-A2 | CORONA DISCHARGE TREATED TRANSDERMAL DELIVERY SYSTEM | Corium, LLC (US) | 2024-05-08 | — | — | EP | claimed |
| EP-4362922-A2 | COMBINATION THERAPY TREATMENT USING TRANSDERMAL DELIVERY SYSTEM | Corium, LLC (US) | 2024-05-08 | — | — | EP | claimed |
| CN-117915898-A | Combination therapy treatment using transdermal delivery systems | 考里安有限责任公司 | 2024-04-19 | — | — | CN | claimed |
| CN-117915897-A | Corona discharge treated transdermal delivery system | 考里安有限责任公司 | 2024-04-19 | — | — | CN | claimed |
| US-20240108587-A1 | SYSTEMS COMPRISING A COMPOSITE BACKING AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | CORIUM, LLC | 2024-04-04 | — | — | US | claimed |
| US-20240091168-A1 | SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | CORIUM, INC. | 2024-03-21 | — | — | US | claimed |
| US-11648214-B2 | Systems and methods for long term transdermal administration | CORIUM, LLC (US) | 2023-05-16 | — | — | US | claimed |
| US-20230072739-A1 | COMBINATION THERAPY TREATMENT USING TRANSDERMAL DELIVERY SYSTEM | CORIUM, LLC | 2023-03-09 | — | — | US | claimed |
| WO-2023278978-A2 | CORONA DISCHARGE TREATED TRANSDERMAL DELIVERY SYSTEM | CORIUM, LLC (US) | 2023-01-05 | — | — | WO | claimed |
| WO-2023278979-A2 | COMBINATION THERAPY TREATMENT USING TRANSDERMAL DELIVERY SYSTEM | CORIUM, LLC (US) | 2023-01-05 | — | — | WO | claimed |
| CN-108697655-B | Systems and methods for long-term transdermal administration | 考里安公司 | 2021-12-10 | — | — | CN | claimed |
| US-20210023020-A1 | SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2021-01-28 | — | — | US | claimed |
| US-10835499-B2 | Systems and methods for long term transdermal administration | CORIUM, INC. (US) | 2020-11-17 | — | — | US | claimed |
| EP-3397250-A1 | SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | Corium International, Inc. (US) | 2018-11-07 | — | — | EP | claimed |
| WO-2017117554-A1 | SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | CORIUM INTERNATIONAL, INC. (US) | 2017-07-06 | — | — | WO | claimed |
| US-20170189348-A1 | SYSTEMS AND METHODS FOR LONG TERM TRANSDERMAL ADMINISTRATION | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2017-07-06 | — | — | US | claimed |
| CN-101362852-B | Method for preparing polybutylene terephthalate/ethylene-vinyl acetate compound material | UNIV SHANGHAI JIAOTONG | 2010-11-17 | — | — | CN | claimed |
| WO-2024145319-A1 | METHOD OF PREPARING TRANSDERMAL DELIVERY SYSTEM | CORIUM, LLC (US) | 2024-07-04 | — | — | WO | disclosed |
| US-4927408-A | For placement on a body surface/delivering agent through | ALZA CORPORATION (US) | 1990-05-22 | — | — | US | disclosed |
| US-4020126-A | TERPOLYMER BLENDS; FILMS, SHEETS, AND ARTICLES MADE USING SUCH BLENDS; AND METHOD OF MAKING TRAYS USING SUCH SHEETS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230072739-A1 | COMBINATION THERAPY TREATMENT USING TRANSDERMAL DELIVERY SYSTEM | MAPT, PSEN2, ACHE | TSHR 2988/4885TP53 1757/4885ELANE 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.